


OBJECTIVE

To assess current clinical practices of clinicians related to management of adult attention-deficit hyperactivity disorder (ADHD) in order to identify knowledge, competency, and practice gaps and barriers to optimal care.




METHODS

A survey instrument of 20 multiple choice questions on current practices, attitudes, and barriers related to the care of patients with ADHD was developed. The survey was available online to physicians without monetary compensation or charge. Responses were de-identified and aggregated prior to analyses. Initial data collection occurred from 11/7/2023 to 11/28/2023.




RESULTS

In total, **753 clinicians** consisting of psychiatrists, primary care physicians, pediatricians, nurse practitioners, and physician assistants completed the survey.




GAPS IN KNOWLEDGE AND COMPETENCE WERE IDENTIFIED IN SEVERAL ASPECTS OF ADULT ADHD CARE.

CLINICAL PRACTICE ASSESSMENT OUTCOMES THEME ANALYSIS - % CORRECT




MOST CLINICIANS BELIEVE THAT FDA-APPROVED MEDICATIONS FOR ADULT ADHD SHOULD BE AVAILABLE TO THEIR PATIENTS WITHOUT PRIOR APPROVAL.

RATE YOUR OPINION ON THE FOLLOWING STATEMENT: ALL FDA-APPROVED MEDICATIONS FOR ADULT ADHD SHOULD BE AVAILABLE TO MY PATIENTS WITHOUT PRIOR APPROVAL.



CLINICIANS CONSIDER "STEP THROUGH" PRIOR AUTHORIZATION WITH A STIMULANT TREATMENT A HINDRANCE TO NONSTIMULANT TREATMENT SELECTION FOR AT LEAST SOME OF THEIR ADULT PATIENTS.

HOW OFTEN IS A "STEP THROUGH" PRIOR AUTHORIZATION WITH A STIMULANT TREATMENT A HINDRANCE TO NONSTIMULANT TREATMENT SELECTION FOR YOUR ADULT PATIENTS WITH ADHD?



CONCLUSIONS

This educational research on assessment of clinicians' knowledge and clinical practices yielded important insights into gaps related to adult ADHD care.


ACKNOWLEDGEMENTS

Developed through independent educational grant from Supernus Pharmaceuticals, Inc.


For more information, contact:
Jovana Lubarda, PhD, Director Medical Education
jlubarda@medscape.net

ABOUT TWO-THIRDS OF CLINICIANS ARE SWITCHING SOME OF THEIR ADULT PATIENTS WITH ADHD TO A NONSTIMULANT, WHILE ONE-THIRD OF CLINICIANS COMBINE THE USE OF STIMULANT AND NONSTIMULANT TREATMENT.

DUE TO THE SHORTAGE WITH STIMULANTS, HOW OFTEN ARE YOU SWITCHING YOUR ADULT PATIENTS WITH ADHD TO A NONSTIMULANT MEDICATION?




HOW OFTEN DO YOU COMBINE THE USE OF STIMULANT AND NONSTIMULANT TREATMENT IN ADULT PATIENTS WITH ADHD?




WHILE LACK OF EFFICACY AND PATIENT RELUCTANCE ARE THE MAIN BARRIERS TO THE USE OF ATOMOXETINE, UNFAMILIARITY WITH VILOXAZINE IS THE MAJOR BARRIER FOR ITS USE.

WHAT IS YOUR PRIMARY BARRIER TO USING ATOMOXETINE IN YOUR ADULT PATIENTS WITH ADHD?



WHAT IS YOUR PRIMARY BARRIER TO USING VILOXAZINE IN YOUR ADULT PATIENTS WITH ADHD?



Scan here to view this poster online.